Clinical significance of CD99 down-regulation in gastric adenocarcinoma

Clinical Cancer Research

Volumn 13, Issue 9, 2007, Pages 2584-2591

  Jung, Hyun Lee ^a   Kim, Seok Hyung ^d   Wang, Li Hui ^a,e   Choi, Yoon La ^c   Young, Chul Kim ^b   Jin, Hee Kim ^b   Tae, Sung Park ^b   Hong, Yun Chul ^b   Young, Kee Shin ^a  

^a Seoul National University   (South Korea)

^b Seoul National University   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Chungbuk National University College of Medicine   (South Korea)

^e SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD99 ANTIGEN; CELL ADHESION MOLECULE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SP1;

ARTICLE; CD99 GENE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE LOCUS; HETEROZYGOSITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; METHYLATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; STOMACH CARCINOMA;

ADENOCARCINOMA; ANTIGENS, CD; CELL ADHESION MOLECULES; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; PROMOTER REGIONS (GENETICS); SP1 TRANSCRIPTION FACTOR; STOMACH NEOPLASMS;

EID: 34249048364     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1785     Document Type: Article

References (34)

1. Crew KD, Neugut AI. Epidemiology of upper gastrointestinal malignancies. Semin Oncol 2004;31:450-64.
2. Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, Nakayama H. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 2005;8:86-94.
3. Mayer B, Jauch KW, Gunthert U, et al. De-novo expression of CD44 and survival in gastric cancer. Lancet 1993;342:1019-22.
4. Saito H, Tsujitani S, Katano K, Ikeguchi M, Maeta M, Kaibara N. Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma. Cancer 1998;83:1094-101.
5. Songun I, Litvinov SV, van de Velde CJ, Pals ST, Hermans J, van Krieken JH. Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. Br J Cancer 2005;92:1767-72.
6. Yamamichi K, Uehara Y, Kitamura N, Nakane Y, Hioki K. Increased expression of CD44v6 mRNA significantly correlates with distant metastasis and poor prognosis in gastric cancer. Int J Cancer 1998;79:256-62.
7. Wang HD, Ren J, Zhang L. CDH1 germline mutation in hereditary gastric carcinoma. World J Gastroenterol 2004;10:3088-93.
8. Ino Y, Gotoh M, Sakamoto M, Tsukagoshi K, Hirohashi S. Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasis. Proc Natl Acad Sci U S A 2002;99:365-70.
9. Shimada Y, Yamasaki S, Hashimoto Y, et al. Clinical significance of dysadherin expression in gastric cancer patients. Clin Cancer Res 2004;10:2818-23.
10. Gelin C, Aubrit F, Phalipon A, et al. The E2 antigen, a 32 kd glycoprotein involved in T-cell adhesion processes, is the MIC2 gene product. EMBO J 1989;8:3253-9.
11. + thymocytes. J Immunol 1995;154:26-32.
12. Cassuto-Viguier E, Ticchioni M, Bernard-Pomier G, et al. Differential effects of antilymphocyte globulins on lymphocytic molecules (E2 and CD2) implicated in the rosette phenomenon. Transplant Proc 1993;25:2322-4.
13. Kim SH, Choi EY, Shin YK, et al. Generation of cells with Hodgkin's and Reed-Sternberg phenotype through downregulation of CD99 (Mic2). Blood 1998;92:4287-95.
14. Bernard G, Breittmayer JP, de Matteis M, et al. Apoptosis of immature thymocytes mediated by E2/CD99. J Immunol 1997;158:2543-50.
15. Pettersen RD, Bernard G, Olafsen MK, Pourtein M, Lie SO. CD99 signals caspase-independent T cell death. J Immunol 2001;166:4931-42.
16. Schenkel AR, Mamdouh Z, Chen X, Liebman RM, Muller WA. CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat Immunol 2002;3:143-50.
17. Kim SH, Shin YK, Lee IS, et al. Viral latent membrane protein 1 (LMP-1)-induced CD99 down-regulation in B cells leads to the generation of cells with Hodgkin's and Reed-Sternberg phenotype. Blood 2000;95:294-300.
18. Stevenson AJ, Chatten J, Bertoni F, Miettinen M. CD-99 (p30/p32 MIC-2) neuroectodermal/Ewing's sarcoma antigen as an immunohistochemical marker. Appl Immunohistochem 1994;2:231-40.
19. Dworzak MN, Fritsch G, Fleischer C, et al. CD99 (MIC2) expression in paediatric B-lineage leukaemia/lymphoma reflects maturation-associated patterns of normal B-lymphopoiesis. Br J Haematol 1999;105:690-5.
20. Folpe AL, McKenney JK, Bridge JA, Weiss SW. Sclerosing rhabdomyosarcoma in adults: report of four cases of a hyalinizing, matrix-rich variant of rhabdomyosarcoma that may be confused with osteosarcoma, chondrosarcoma, or angiosarcoma. Am J Surg Pathol 2002;26:1175-83.
21. Choi YL, Kim HS, Ahn G. Immunoexpression of inhibin alpha subunit, inhibin/activin betaA subunit and CD99 in ovarian tumors. Arch Pathol Lab Med 2000;124:563-9.
22. Goto A, Niki T, Terado Y, Fukushima J, Fukayama M. Prevalence of CD99 protein expression in pancreatic endocrine tumours (PETs). Histopathology 2004;45:384-92.
23. Choi YL, Xuan YH, Shin YK, et al. An immunohistochemical study of the expression of adhesion molecules in gallbladder lesions. J Histochem Cytochem 2004;52:591-601.
24. Jung KC, Park WS, Bae YM, et al. Immunoreactivity of CD99 in stomach cancer. J Korean Med Sci 2002;17:483-9.
25. Wang LH, Kim SH, Lee JH, et al. Inactivation of SMAD4 tumor suppressor gene during gastric carcinoma progression. Clin Cancer Res 2007;13:102-110.
26. Wang LH, Choi YL, Hua XY, et al. Increased expression of sonic hedgehog and altered methylation of its promoter region in gastric cancer and its related lesions. Mod Pathol 2006;19:675-83.
27. Wang C, Horiuchi A, Imai T, et al. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J Pathol 2004;202:215-23.
28. Lee I, Kim MK, Choi EY et al. CD99 expression is positively regulated by Sp1 and is negatively regulated by Epstein-Barr virus latent membrane protein 1 through nuclear factor-kappaB. Blood 2001;97:3596-604.
29. Lee IS, Shin YK, Chung DH, Park SH. LMP1-induced downregulation of CD99 molecules in Hodgkin and Reed-Sternberg cells. Leuk Lymphoma 2001;42:587-94.
30. Cerisano V, Aalto Y, Perdichizzi S, et al. Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators. Oncogene 2004;23:5664-74.
31. Tatematsu M, Tsukamoto T, Inada K. Stem cells and gastric cancer: role of gastric and intestinal mixed intestinal metaplasia. Cancer Sci 2003;94:135-41.
32. Manara MC, Bernard G, Lollini PL, et al. CD99 acts as an oncosuppressor in osteosarcoma. Mol Biol Cell 2006;17:1910-21.
33. Shiratori I, Ogasawara K, Saito T, Lanier LL, Arase H. Activation of natural killer cells and dendritic cells up-on recognition of a novel CD99-like ligand by paired immunoglobulin-like type 2 receptor. J Exp Med 2004;199:525-33.
34. Park SH, Shin YK, Suh YH, et al. Rapid divergency of rodent CD99 orthologs: implications for the evolution of the pseudoautosomal region. Gene 2005;353:177-88.